The lawsuit claims that throughout the specified class period, ADMA Biologics made materially false or misleading statements. According to the complaint, the company allegedly failed to disclose an undisclosed related party transaction and employed channel stuffing to artificially inflate reported revenue. Furthermore, the suit alleges the firm lacked adequate internal controls, rendering its public statements about business operations and financial prospects baseless.

Investors who incurred losses are not required to take immediate action to remain part of the potential class, as no class has yet been certified. However, those seeking to act as lead plaintiff must file a motion with the court by the August 10 deadline. Representation by The Rosen Law Firm is not mandatory, and investors retain the right to select their own legal counsel or remain absent class members. The firm notes that the ability to participate in any potential future recovery does not depend on serving as a lead plaintiff in the proceedings.